Genmab's Darzalex still going strong after two years in newly diagnosed patients

After two years of follow-ups, the addition of Genmab's Darzalex to standard treatments of multiple myeloma still ensures certain patients a progression free survival. In fact, the combination is more effective than the standard therapy alone.

Photo: /Ritzau Scanpix/Nikolai Linares

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles